1. Biopharma execs address the challenges of a post-pandemic workplace — Bristol Myers pays $200M upfront plus $1.36B in biobucks for Agenus' preclinical TIGIT asset — Novo Nordisk nets Ph2 win for former Corvidia kidney programSee more on our front page news
    Dismiss Notice


Discussion in 'Philips Pathology' started by Anonymous, Oct 27, 2011 at 2:15 PM.

  1. Anonymous

    Anonymous Guest

    There it is!